{"contentid": 488486, "importid": NaN, "name": "GSK sees sales slump due to COVID-19 disruption", "introduction": "Sales and earnings were down at UK drugmaker GlaxoSmithKline in the group\u00e2\u0080\u0099s first quarter 2021 financial results, albeit no worse than expected.", "content": "<p>Sales and earnings were down at UK drugmaker GlaxoSmithKline (LSE: GSK) in the group&rsquo;s first quarter 2021 financial results, albeit no worse than expected.</p>\n<p>Turnover dropped 18% to &pound;7.42 billion ($10.3 billion), caused partly by a 32% slump in sales in the Vaccines division, with governments prioritizing the rollout of COVID-19 jabs ahead of the likes of GSK&rsquo;s Shingrix, revenue from which was down by nearly half. In the Pharmaceuticals unit, revenue fell 12% to &pound;3.9 billion.</p>\n<p>Total earnings per share (EPS) were &pound;0.22, 32% lower than the same period last year but in line with expectations due to the anticipated impact of the pandemic.</p>\n<p>The company has reconfirmed its 2021 guidance, with a decline of mid to high single-digit percentage points in adjusted EPS predicted for the full year, at constant exchange rates.</p>\n<p>GSK said it is on track to complete its split, creating the New GSK and New Consumer Healthcare companies, in 2022.</p>\n<p>Shares in GSK were broadly unchanged as Wednesday&rsquo;s trading day neared its end in London.</p>\n<p>Emma Walmsley, chief executive of GSK, said: &ldquo;Our first quarter results are in line with our expectations and reflect the anticipated impacts of COVID-19. We continue to expect a significant improvement in performance over the remainder of the year and reconfirm our guidance for 2021 and 2022 outlook.</p>\n<p>&ldquo;The launch of Cabenuva (cabotegravir/rilpivirine) for HIV and Phase III starts for our RSV vaccine and a new long-acting treatment for severe asthma are key milestones as we continue to strengthen our growth prospects. Separation plans are also well underway and we look forward to sharing our strategy and growth outlook for New GSK with investors in June.&rdquo;</p>\n<h2>Key product sales</h2>\n<p>Seretide/Advair (fluticasone/salmeterol): &pound;351 million, down 11%</p>\n<p>Relvar/Breo Ellipta (fluticasone furoate/vilanterol): &pound;268 million, down 6%</p>\n<p>Triumeq (abacavir/dolutegravir/lamivudine): &pound;436 million, down 23%</p>\n<p>Tivicay (dolutegravir): &pound;301 million, down 27%</p>\n<p>Shingrix: &pound;327 million, down 49%</p>", "date": "2021-04-28 16:19:00", "meta_title": NaN, "meta_keywords": "sales, COVID-, earnings, quarter, results, slump, billion, million, sees, disruption, drugmaker, GlaxoSmithKline, albeit, worse, expected, financial, year", "meta_description": "Sales and earnings were down at UK drugmaker GlaxoSmithKline (LSE: GSK) in the group\u00e2\u0080\u0099s first quarter financial results, albeit no worse than expected.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-28 15:20:54", "updated": "2021-04-28 16:21:40", "access": NaN, "url": "https://www.thepharmaletter.com/article/gsk-sees-sales-slump-due-to-covid-19-disruption", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "gsk_glaxosmithkline_hq_large.jpg", "image2id": "gsk_glaxosmithkline_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Anti-virals, Infectious diseases, Respiratory and Pulmonary, Vaccines", "topic_tag": "Coronavirus, Financial, Focus On, Management", "geography_tag": "UK", "company_tag": "GlaxoSmithKline", "drug_tag": "Breo Ellipta, Relvar Ellipta, Seretide/Advair, Shingrix, Tivicay, Triumeq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-28 16:19:00"}